GO
Loading...

Dendreon Down

Wednesday, 9 May 2007 | 9:16 AM ET

The FDA requested additional information from Dendreon on Provenge, the company's prostate cancer drug, and the stock collapsed as a result. Mike Huckman, CNBC pharmaceuticals reporter, has the details.